Since 2005, the American Psychiatric Association has recommended BLT as a treatment option for patients with major depressive ...

Depression and anxiety rank among the top global health challenges. Since 1990, these disorders have surged, placing them in ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...